Community Pharmacists Vaccinate Against Cancer

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Human Papillomavirus Vaccines
Interventions
BEHAVIORAL

Community Pharmacists Vaccinating Against Cancer

Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.

Trial Locations (1)

85201

Adelante Healthcare Mesa, Mesa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Adelante Healthcare

UNKNOWN

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

lead

Arizona State University

OTHER